rabeprazole / Generic mfg. - LARVOL DELTA

Gastroesophageal Intussusception After Peroral Endoscopic Myotomy for Achalasia in an Adult: Case Report and Literature Review (ACG 2026) - "His symptoms had previously been controlled with vonoprazan but recurred after transitioning to rabeprazole. Figure: EGD showing severe distal esophagitis and respiratory-dependent gastroesophageal intussusception. Figure: Computed tomography of the abdomen and pelvis shows a small hiatal hernia and distal esophageal dilation (green arrow) but no evidence of gastroesophageal intussusception."

Case report • Clinical • Review • Cardiovascular • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Lupus • Rare Diseases

A Twist in the Tale: An Unusual Case of Squamous Cell Carcinoma in Barrettâs Esophagus (ACG 2026) - "His proton pump inhibitor therapy was escalated to rabeprazole 20 mg twice daily with initial improvement; prior dexlansoprazole trials had been ineffective...A single medium, submucosal nodule in the mid esophagus located 35 cm from the incisors. Biopsies were taken with cold forceps for histology and revealed poorly differentiated squamous cell carcinoma."

Clinical • Barrett Esophagus • Esophageal Adenocarcinoma • Gastrointestinal Disorder • Oncology • Solid Tumor • Squamous Cell Carcinoma

Proton Pump Inhibitor-Associated Rhabdomyolysis: A Systematic Review of Pharmacovigilance Disproportionality Studies (ACG 2026) - "Pantoprazole was the weakest and nonsignificant in the Italian data (ROR 1.15; 95% CI 0.90-1.49). From 251 records, 196 were screened after duplicate removal. A disproportionate signal linking PPIs to rhabdomyolysis was identified across all three databases, with the magnitude varying by agent. In FAERS, all five PPIs showed significant RORs, with lansoprazole the strongest (ROR 12.67; 95% CI 11.66-13.77); esomeprazole, omeprazole, and rabeprazole were consistently significant across FAERS and JADER."

Adverse events • Review • Musculoskeletal Pain • ROR1

Longitudinal Gut Resistome Remodeling and Phenotype-Specific Refractory GERD Outcomes During P-CAB Versus PPI Therapy: Prospective Multicenter Data from India (ACG 2026) - "A total of 1,300 patients were enrolled, including 783 males (60.2%) and 517 females (39.8%). Patients received either vonoprazan-based P-CAB therapy (20 mg daily; n=650) or esomeprazole/rabeprazole-based PPI therapy (40 mg daily; n=650). Mean age was 44.6±11.8 years (95% CI 43.9â45.2)."

Clinical • Gastroenterology • Gastroesophageal Reflux Disease • Immunology

Concomitant Proton Pump Inhibitor Use and IBD-Related Outcomes After GLP-1 Receptor Agonist Initiation (ACG 2026) - "Adults with Crohnâs disease or ulcerative colitis initiating GLP-1 therapy were stratified by PPI exposure, defined by omeprazole, pantoprazole, lansoprazole, esomeprazole, rabeprazole, or dexlansoprazole use. Before propensity score matching, 8,329 patients were identified in the PPI-exposed cohort and 4,504 in the non-PPI-exposed cohort. After matching, 2,943 patients remained in each cohort. Among patients eligible for incident outcome analysis after excluding those with the composite outcome before initiating GLP-1 therapy, the primary outcome occurred in 210/648 patients (32.4%) with PPI exposure and 140/710 patients (19.7%) without PPI exposure."

Crohn's disease • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammatory Bowel Disease • Obesity • Ulcerative Colitis

When PPIs Fail: Rapid Resolution of Refractory Post-POEM Esophagitis With Vonoprazan (ACG 2026) - "Pantoprazole was subsequently switched to rabeprazole 20 mg bid but there was no improvement in symptoms and reflux stricturing. Pre-vonoprazan upper endoscopic findings showing (A) ulceration at the gastroesophageal junction and (B) reflux esophagitis with stenosis of the gastroesophageal junction Figure: Figure 2. Upper endoscopic findings obtained 4 months after vonoprazan treatment showing (A) a normal gastroesophageal junction and (B) a normal distal esophagus"

Gastroenterology • Gastrointestinal Disorder • Rare Diseases

Not All Proton Pump Inhibitors Are Equal: A Head-to-Head Safety Comparison of All Six Oral Agents in 954,252 Propensity-Matched Adults (ACG 2026) - "Six mutually exclusive cohorts excluded other study PPIs, H2-receptor antagonists, or vonoprazan within 1 year before or any time after index. 954,252 patients met criteria (pantoprazole 247,382; omeprazole 562,141; esomeprazole 87,754; lansoprazole 35,077; dexlansoprazole 13,297; rabeprazole 8,601). All post-match standardized mean differences were < 0.10. Dexlansoprazole and rabeprazole showed the lowest adverse-event burden â each significantly more favorable than the other four, with no significant difference between them (RR 1.008, 95% CI 0.927â1.095)."

Clinical • Head-to-Head • Acute Kidney Injury • Alzheimer's Disease • Chronic Kidney Disease • CNS Disorders • Dementia • Hematological Disorders • Infectious Disease • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Pneumonia • Renal Disease • Respiratory Diseases

Insurance Coverage and Patient Out-of-Pocket Costs Influence Physicians in Choosing Off-Label Over FDA-Approved Treatments for Patients With Eosinophilic Esophagitis: Results From a U.S. Physician Survey (ACG 2026) - "PPIs were dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole and vonoprazan (although vonoprazan is not a PPI, it is a potassium-competitive acid blocker and is included as part of this group for the purposes of this survey); â For example, elemental diet, 6-/4-/2-food elimination diet; â¡Off-label swallowed topical corticosteroids were inhaled budesonide and fluticasone propionate formulations that are swallowed, rather than inhaled (off-label use); §Systemic corticosteroids were betamethasone, hydrocortisone and prednisone. In total, 100 physicians completed the survey (gastroenterologists, 36%; allergists/immunologists, 35%; primary care providers, 29%); the majority had been practicing for >15 years. Proton-pump inhibitors (PPIs), dietary intervention and off-label swallowed topical corticosteroids were the most common first-line treatments for adults with EoE. FDA-approved treatments, BOS and dupilumab, were..."

Clinical • Reimbursement • US reimbursement • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology

Beyond Acid Suppression: Real-World Enteric Infection and All-Cause Mortality Outcomes With Vonoprazan Versus Proton Pump Inhibitor in Gastroesophageal Reflux Disease (ACG 2026) - "The exposure group included vonoprazan monotherapy, and the comparator group included pooled PPI monotherapy (dexlansoprazole, esomeprazole, rabeprazole, lansoprazole, omeprazole, and pantoprazole). After PSM, 6,721 patients were included in each cohort. Vonoprazan was associated with a higher risk of non-CDI enteric infection compared with pooled PPIs (5.6% vs 2.5%; RR 2.23; OR 2.30; HR 2.69, 95% CI 2.21â3.27). This association remained consistent across all individual PPI subgroup analyses."

Clinical • Real-world • Real-world evidence • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Infectious Disease

A Rare Case of Lichenoid Esophagitis in a Patient With Comorbid Leukocytoclastic Vasculitis and Antiphospholipid Syndrome (ACG 2026) - "Prior therapies including omeprazole, rabeprazole, oral budesonide, systemic prednisone, topical fluticasone, methotrexate, and dapsone were reported to be ineffective...Due to concerns for steroid-related complications, the patient was transitioned to oral tacrolimus 1 mg twice a day...While the predominant mechanisms of autoimmunity differ, this case suggests a possible association between LE and comorbid LCV and/or APS which warrants further investigation. Figure: Image 1: Esophageal stenosis of proximal esophagus 15 cm from the incisors found on baseline EGD in December, 2024 Figure: Image 2: Esophageal stenoses (narrowest 8 mm inner diameter by 1 cm length) found on EGD in September, 2025"

Clinical • Alopecia • Dermatomyositis • Dermatopathology • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Lichen Planus • Metabolic Disorders • Myositis • Sjogren's Syndrome • Type 1 Diabetes Mellitus • Vasculitis

A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014) (clinicaltrials.gov) - P1 | N=196 | Completed | Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

New P1 trial

EFFICACY AND SAFETY OF ANAPRAZOLE VERSUS RABEPRAZOLE IN EROSIVE ESOPHAGITIS (LOS ANGELES GRADES B-D): A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III NON-INFERIORITY TRIAL (UEGW 2026) - No abstract available

Clinical • Head-to-Head • Late-breaking abstract • P3 data • Gastrointestinal Disorder

Cytochrome P450 Enzymes in the Metabolism of Proton Pump Inhibitors: Implications for the Treatment of Peptic Ulcers. (PubMed, Curr Drug Targets) - "Incorporating CYP2C19 genotyping and pharmacogenomic data into clinical decisionmaking may improve treatment individualization, although evidence remains heterogeneous and context-dependent."

Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Metabolic Disorders • Peptic Ulcer • CYP2C19 • CYP3A4

A Study of RO7890597 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=139 | Recruiting | Sponsor: Genentech, Inc.

New P1 trial

A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Hutchmed | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Aug 2026

Trial completion • Trial completion date

Randomized controlled trial comparing 7-day fexuprazan-based and 14-day rabeprazole-based triple therapies for Helicobacter pylori eradication. (PubMed, Medicine (Baltimore)) - "Seven-day fexuprazan-based triple therapy demonstrated eradication efficacy comparable with that of 14-day rabeprazole-based therapy in treatment-naïve Korean patients with H. pylori infection. The fexuprazan-based regimen showed a similar safety profile and comparable incidence of adverse events with that of the rabeprazole-based regimen."

Clinical • Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease

Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: Eli Lilly and Company | N=48 ➔ 1 | Active, not recruiting ➔ Terminated; Original scientific question rendered moot by the external scientific community

Enrollment change • Trial termination

Beyond acid suppression: the multifaceted role of proton pump inhibitors in Helicobacter pylori eradication. (PubMed, Front Microbiol) - "This review provides a comprehensive overview of the pharmacological properties, clinical applications, and current limitations of the most widely used PPIs, including omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole. The review also discusses emerging evidence for interindividual variability in PPI metabolism, drug-drug interactions, and concerns regarding long-term adverse effects of the current treatments. Finally, it highlights potassium-competitive acid blockers (P-CABs), a newer class of acid-suppressive agents that provide sustained acid inhibition and represent a promising alternative to PPI-based regimens for H. pylori eradication."

Journal • Review • Infectious Disease

Differential fracture risk among proton pump inhibitors in older adults: evidence network and pharmacovigilance validation. (PubMed, Front Pharmacol) - "Compared with non-PPI users, omeprazole (OR 1.51, 95%CI 1.36-1.67), rabeprazole (OR 1.47, 95%CI 1.22-1.78), pantoprazole (OR 1.44, 95%CI 1.28-1.62), and lansoprazole (OR 1.32, 95%CI 1.14-1.53) were associated with a significantly increased risk of any-site fracture...Consistent with NMA findings, omeprazole exhibited a significant fracture risk signal (ROR 1.25, 95%CI 1.03-1.51), while esomeprazole showed no significant signal for overall fracture (ROR 0.89, 95%CI 0.66-1.20)...This discordance indicates that absence of a fracture signal should not imply skeletal safety. These findings provide evidence-based guidance for individualized PPI prescribing in elderly patients, with careful benefit-risk assessment for those requiring extended-duration PPI regimens."

Adverse events • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • ROR1

COMPARATIVE EFFICACY OF PANTOPRAZOLE AND RABEPRAZOLE IN COMBINATION WITH MOSAPRIDE FOR REFRACTORY GERD: CLINICAL OUTCOMES AND COST-EFFECTIVENESS IN UKRAINE'S WARTIME ENVIRONMENT (UEGW 2026) - No abstract available

Clinical • Clinical data • Combination therapy • Cost effectiveness • HEOR • Gastroesophageal Reflux Disease

Efficacy And Safety of Bismuth-Tetracycline-Rabeprazole Triple For First-Line Eradication of Helicobacter Pylori Infection (clinicaltrials.gov) - P=N/A | N=300 | Not yet recruiting | Sponsor: Chih-An Shih, MD

New trial • Infectious Disease

Bismuth-Amoxicillin-Vonoprazan Triple, Amoxicillin-Vonoprazan Dual, and Clarithromycin-Based Triple Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Open-Label, Randomized Trial. (PubMed, Helicobacter) - "BAV triple therapy demonstrates superior efficacy compared with AV dual therapy and CAR triple therapy as first-line treatment for H. pylori infection in Taiwan. This regimen represents a promising first-line option that may obviate the need for routine clarithromycin-resistance testing in regions where AV dual therapy yields suboptimal eradication rates."

Clinical • Journal • Infectious Disease

Bioequivalence of two rabeprazole formulations and pharmacokinetic variability by CYP2C19 genotype and sex in healthy Korean participants: A four-period replicated crossover study. (PubMed, Clin Pharmacol Drug Dev) - "The reference formulation showed high intra-CV in maximum plasma concentration (Cmax; 67.9%), consistent with the classification of rabeprazole as a highly variable drug. These results demonstrated bioequivalence between the test and reference formulations under both conventional average bioequivalence and scaled bioequivalence approaches."

Clinical • Journal • PK/PD data • CYP2C19

Rabeprazole exhibits broad-spectrum fusion inhibition against Nipah pseudovirus and authentic HCoV-OC43 and RSV. (PubMed, Bioorg Chem) - "Systematic structure-activity relationship (SAR) profiling among clinically approved PPIs revealed that Ilaprazole and Lansoprazole exhibited stronger anti-NiV potency than Rabeprazole, while Rabeprazole sulfide showed enhanced antiviral activity relative to the parent compound. Rabeprazole also inhibited live RSV and HCoV-229E infection in a dose-dependent manner. Collectively, these findings establish the HR1 groove as a druggable pan-viral target and validate benzimidazole-based PPIs as a versatile scaffold for developing orally available, broad-spectrum antivirals against phylogenetically distinct enveloped viruses that rely on class I fusion machinery."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Decade of Screening and Treating Helicobacter pylori Infection Among First-Year High School Students in Kyoto, Japan: Annual Trends in Infection, Consultation, and Eradication Success Rates (2015-2023). (PubMed, Helicobacter) - "The prospective adolescent screen-and-treat program demonstrated a significant decrease in H. pylori infection rates among first-year high school students over the decade. While the safety and efficacy of the PAM-based eradication regimen were verified, declining medical consultation rates present a continuous challenge for public health implementation."

Journal • Gastric Cancer • Infectious Disease • Oncology • Solid Tumor